These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 24062397)

  • 1. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
    Domingo E; Church DN; Sieber O; Ramamoorthy R; Yanagisawa Y; Johnstone E; Davidson B; Kerr DJ; Tomlinson IP; Midgley R
    J Clin Oncol; 2013 Dec; 31(34):4297-305. PubMed ID: 24062397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
    Midgley RS; McConkey CC; Johnstone EC; Dunn JA; Smith JL; Grumett SA; Julier P; Iveson C; Yanagisawa Y; Warren B; Langman MJ; Kerr DJ
    J Clin Oncol; 2010 Oct; 28(30):4575-80. PubMed ID: 20837956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!
    Fuchs CS; Ogino S
    J Clin Oncol; 2013 Dec; 31(34):4358-61. PubMed ID: 24166520
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aspirin and PIK3CA mutation in colorectal cancer].
    Kirstein MM; Vogel A
    Z Gastroenterol; 2014 Mar; 52(3):306-7. PubMed ID: 24622874
    [No Abstract]   [Full Text] [Related]  

  • 6. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
    Liao X; Lochhead P; Nishihara R; Morikawa T; Kuchiba A; Yamauchi M; Imamura Y; Qian ZR; Baba Y; Shima K; Sun R; Nosho K; Meyerhardt JA; Giovannucci E; Fuchs CS; Chan AT; Ogino S
    N Engl J Med; 2012 Oct; 367(17):1596-606. PubMed ID: 23094721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
    Paleari L; Puntoni M; Clavarezza M; DeCensi M; Cuzick J; DeCensi A
    Clin Oncol (R Coll Radiol); 2016 May; 28(5):317-26. PubMed ID: 26712086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.
    Kothari N; Kim R; Jorissen RN; Desai J; Tie J; Wong HL; Faragher I; Jones I; Day FL; Li S; Sakthinandeswaren A; Palmieri M; Lipton L; Schell M; Teer JK; Shibata D; Yeatman T; Sieber OM; Gibbs P; Tran B
    Acta Oncol; 2015 Apr; 54(4):487-92. PubMed ID: 25549537
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential biomarker for aspirin use in colorectal cancer therapy.
    Langley RE; Rothwell PM
    Nat Rev Clin Oncol; 2013 Jan; 10(1):8-10. PubMed ID: 23207797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
    Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.
    Li P; Wu H; Zhang H; Shi Y; Xu J; Ye Y; Xia D; Yang J; Cai J; Wu Y
    Gut; 2015 Sep; 64(9):1419-25. PubMed ID: 25239119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
    Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
    Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.
    Murphy C; Turner N; Wong HL; Sinnathamby M; Tie J; Lee B; Desai J; Skinner I; Christie M; Hutchinson R; Lunke S; Waring P; Gibbs P; Tran B
    Intern Med J; 2017 Jan; 47(1):88-98. PubMed ID: 27800646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
    Jordan F; Quinn TJ; McGuinness B; Passmore P; Kelly JP; Tudur Smith C; Murphy K; Devane D
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD011459. PubMed ID: 32352165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival.
    Hua X; Phipps AI; Burnett-Hartman AN; Adams SV; Hardikar S; Cohen SA; Kocarnik JM; Ahnen DJ; Lindor NM; Baron JA; Newcomb PA
    J Clin Oncol; 2017 Aug; 35(24):2806-2813. PubMed ID: 28617623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
    Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
    Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.
    Shoji H; Yamada Y; Taniguchi H; Nagashima K; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Cancer Sci; 2014 Aug; 105(8):1002-7. PubMed ID: 24863535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
    Chen Z; Wang C; Dong H; Wang X; Gao F; Zhang S; Zhang X
    Mol Med; 2020 Jan; 26(1):14. PubMed ID: 32000660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VICTOR spoiled?
    Goldberg RM; Bertagnolli MM
    J Clin Oncol; 2010 Oct; 28(30):4546-8. PubMed ID: 20837951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.